Abstract
No public abstract is available from the verified source records.
Cory R. Trankle, Wendy Bottinor, Jennifer H. Jordan, W. Gregory Hundley
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
openalex
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia
10.1038/s41569-020-0348-1 · 2020
Cardiovascular magnetic resonance in the oncology patient
10.1016/j.jcmg.2018.06.004 · 2018
Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography
10.1056/nejm197902083000603 · 1979
Defining cardiovascular toxicities of cancer therapies: an International cardio-oncology society (IC-OS) consensus statement
10.1093/eurheartj/ehab674 · 2022
Simultaneous left ventricular volume and strain changes during chemotherapy associate with 2‐year postchemotherapy measures of left ventricular ejection fraction
10.1161/jaha.119.015400 · 2020
Prevalence of cardiovascular disease in patients with potentially curable malignancies
10.1016/j.jaccao.2022.03.004 · 2022
Stress cardiac magnetic resonance myocardial perfusion imaging
10.1016/j.jacc.2021.08.022 · 2021
Anthracycline-associated T1 mapping characteristics are elevated independent of the presence of cardiovascular comorbidities in cancer survivors
10.1161/circimaging.115.004325 · 2016
CMR imaging biosignature of cardiac involvement due to cancer-related treatment by T1 and T2 mapping
10.1016/j.ijcard.2018.10.023 · 2019
Occult cardiotoxicity in childhood cancer survivors exposed to anthracycline therapy
10.1161/circimaging.113.000798 · 2013
2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis
10.1016/j.jacc.2022.11.022 · 2023
Spectrum of restrictive and infiltrative cardiomyopathies: part 2 of a 2-part series
10.1016/j.jacc.2018.01.017 · 2018
Characterization of critically ill patients with septic shock and sepsis‐associated cardiomyopathy using cardiovascular MRI
10.1002/ehf2.13938 · 2022
Stress cardiomyopathy diagnosis and treatment: JACC state-of-the-art review
10.1016/j.jacc.2018.07.072 · 2018
Takotsubo and cancer
10.1093/eurheartj/ehaa175 · 2020
Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis
10.1093/eurheartj/ehaa051 · 2020
Anticancer therapy–related increases in arterial stiffness: a systematic review and meta‐analysis
10.1161/jaha.119.015598 · 2020
Left ventricular mass change after anthracycline chemotherapy
2018
Left ventricle size correlates with peak exercise capacity in pediatric cancer survivors exposed to anthracycline chemotherapy
10.1007/s00246-023-03192-z · 2023
Cardiac tumors
10.1016/j.jaccao.2020.05.009 · 2020
Cardiovascular magnetic resonance imaging in suspected cardiac tumour: a multicentre outcomes study
10.1093/eurheartj/ehab635 · 2021
2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American college of cardiology/American heart association joint committee on clinical practice guidelines
2021
Cardiac magnetic resonance imaging in the evaluation of the late effects of anthracyclines among long-term survivors of childhood cancer
10.1016/j.jacc.2013.01.019 · 2013
Longitudinal assessment of right ventricular structure and function by cardiovascular magnetic resonance in breast cancer patients treated with trastuzumab: a prospective observational study
10.1186/s12968-017-0356-4 · 2017
2022 ESC guidelines on cardio-oncology developed in collaboration with the European hematology association (EHA), the European society for therapeutic radiology and oncology (ESTRO) and the international cardio-oncology society (IC-OS)
10.1093/eurheartj/ehac244 · 2022
Unresolved referenced work
Kept as external metadata until matched
Screening adult survivors of childhood cancer for cardiomyopathy: comparison of echocardiography and cardiac magnetic resonance imaging
10.1200/jco.2011.40.3584 · 2012
Left ventricular mass in patients with a cardiomyopathy after treatment with anthracyclines
10.1016/j.amjcard.2012.07.040 · 2012
Increased need for right ventricular support in patients with chemotherapy-induced cardiomyopathy undergoing mechanical circulatory support
10.1016/j.jacc.2013.09.040 · 2014
Cardiovascular imaging in contemporary cardio-oncology: a scientific statement from the american heart association
10.1161/cir.0000000000001174 · 2023
Simultaneous exercise stress cardiac magnetic resonance and cardiopulmonary exercise testing to elucidate the Fick components of aerobic exercise capacity: a feasibility and reproducibility study and pilot study in hematologic cancer survivors
10.1186/s40959-023-00182-1 · 2023
Simultaneous exercise stress cardiac magnetic resonance and cardiopulmonary exercise testing to elucidate the Fick components of aerobic exercise capacity: a feasibility and reproducibility study and pilot study in hematologic cancer survivors
10.1186/s40959-023-00182-1 · doi-reference
Cardiovascular imaging in contemporary cardio-oncology: a scientific statement from the american heart association
10.1161/cir.0000000000001174 · doi-reference
Increased need for right ventricular support in patients with chemotherapy-induced cardiomyopathy undergoing mechanical circulatory support
10.1016/j.jacc.2013.09.040 · doi-reference
Left ventricular mass in patients with a cardiomyopathy after treatment with anthracyclines
10.1016/j.amjcard.2012.07.040 · doi-reference
Screening adult survivors of childhood cancer for cardiomyopathy: comparison of echocardiography and cardiac magnetic resonance imaging
10.1200/jco.2011.40.3584 · doi-reference
2022 ESC guidelines on cardio-oncology developed in collaboration with the European hematology association (EHA), the European society for therapeutic radiology and oncology (ESTRO) and the international cardio-oncology society (IC-OS)
10.1093/eurheartj/ehac244 · doi-reference
Longitudinal assessment of right ventricular structure and function by cardiovascular magnetic resonance in breast cancer patients treated with trastuzumab: a prospective observational study
10.1186/s12968-017-0356-4 · doi-reference
Cardiac magnetic resonance imaging in the evaluation of the late effects of anthracyclines among long-term survivors of childhood cancer
10.1016/j.jacc.2013.01.019 · doi-reference
Cardiovascular magnetic resonance imaging in suspected cardiac tumour: a multicentre outcomes study
10.1093/eurheartj/ehab635 · doi-reference
Cardiac tumors
10.1016/j.jaccao.2020.05.009 · doi-reference
Left ventricle size correlates with peak exercise capacity in pediatric cancer survivors exposed to anthracycline chemotherapy
10.1007/s00246-023-03192-z · doi-reference
Anticancer therapy–related increases in arterial stiffness: a systematic review and meta‐analysis
10.1161/jaha.119.015598 · doi-reference
Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis
10.1093/eurheartj/ehaa051 · doi-reference
Takotsubo and cancer
10.1093/eurheartj/ehaa175 · doi-reference
Stress cardiomyopathy diagnosis and treatment: JACC state-of-the-art review
10.1016/j.jacc.2018.07.072 · doi-reference
Characterization of critically ill patients with septic shock and sepsis‐associated cardiomyopathy using cardiovascular MRI
10.1002/ehf2.13938 · doi-reference
Spectrum of restrictive and infiltrative cardiomyopathies: part 2 of a 2-part series
10.1016/j.jacc.2018.01.017 · doi-reference
2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis
10.1016/j.jacc.2022.11.022 · doi-reference
Occult cardiotoxicity in childhood cancer survivors exposed to anthracycline therapy
10.1161/circimaging.113.000798 · doi-reference
CMR imaging biosignature of cardiac involvement due to cancer-related treatment by T1 and T2 mapping
10.1016/j.ijcard.2018.10.023 · doi-reference
Anthracycline-associated T1 mapping characteristics are elevated independent of the presence of cardiovascular comorbidities in cancer survivors
10.1161/circimaging.115.004325 · doi-reference
Stress cardiac magnetic resonance myocardial perfusion imaging
10.1016/j.jacc.2021.08.022 · doi-reference
Prevalence of cardiovascular disease in patients with potentially curable malignancies
10.1016/j.jaccao.2022.03.004 · doi-reference
Simultaneous left ventricular volume and strain changes during chemotherapy associate with 2‐year postchemotherapy measures of left ventricular ejection fraction
10.1161/jaha.119.015400 · doi-reference
Defining cardiovascular toxicities of cancer therapies: an International cardio-oncology society (IC-OS) consensus statement
10.1093/eurheartj/ehab674 · doi-reference
Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography
10.1056/nejm197902083000603 · doi-reference
Cardiovascular magnetic resonance in the oncology patient
10.1016/j.jcmg.2018.06.004 · doi-reference
Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia
10.1038/s41569-020-0348-1 · doi-reference